Hemoptysis Clinical Trial
Official title:
Development and Application of a New Balloon Catheter for Intraairway Hemostasis
Massive hemoptysis is a serious disease of respiratory system, which seriously endangers the life of patients. There are obvious difficulties in the treatment of hemoptysis. In the traditional treatment, patients still have the risk of massive hemoptysis and suffocation, and the risk control in the treatment process cannot be ensured. Intra - airway interventional therapy, especially the hemostatic technique of intra - airway balloon catheter, is an important means to control the risk of hemoptysis. However, the current intraairway balloon catheter therapy technology is immature, complicated and difficult to operate, and the cost is high. There is a lack of special balloon for hemostasis, and the balloon borrowed for other purposes cannot meet the needs of hemoptysis treatment. Therefore, it is urgent to develop a new balloon catheter for airway hemostasis, which has simple technical operation, easy to master and popularize, efficient and safe function and structure. According to this requirement, this project designed and developed hemostatic balloon catheter with multiple functions such as self-guiding, anti-displacement, anti-leakage and detachable rear end, so as to make the treatment of massive hemoptysis more safe and effective, simpler and faster, so as to be widely applied in clinical practice.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | October 30, 2023 |
Est. primary completion date | October 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - The patients were 18-75 years, male or non-pregnant female; - Meet the clinical definition of massive hemoptysis (blood loss =100ml each time or =500ml 24h); - The patient/legal authorized representative understood the purpose and procedure of the test and voluntarily signed the informed consent. Exclusion Criteria: - Patients and their family members have no subjective treatment intention;Patients fail to cooperate or sign preoperative informed consent; - The obvious effect of balloon catheter therapy is not ideal; - Severe arrhythmia, acute myocardial ischemia; - blood pressure is not effectively controlled (diastolic blood pressure =95mmHg or systolic blood pressure =150mmHg); - Severe coagulopathy; - Severe organ insufficiency (except respiratory insufficiency); - Allergic to narcotic drugs; - Pregnant women, those who are breast-feeding or trying to conceive; - Patients who do not wish to sign informed consent; - Patients who failed to follow up; - Other patients deemed unsuitable for the study by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | The first affiliated hospital of wenzhou medical university | Wenzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Wenzhou Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immediate intraoperative success rate | Immediate intraoperative success rate | Immediately after surgery | |
Primary | Success rate of hemostasis 1 day after operation | Success rate of hemostasis 1 day after operation | 1 day after operation | |
Primary | Intraoperative complication | Significant increase in hemoptysis requiring other emergency management or suspension of operations, asphyxia, death, new arrhythmias, persistent worsening hypoxemia. | During surgery | |
Secondary | Success rate of hemostasis 3 days and 1 and 2 weeks after operation | Success rate of hemostasis 3 days and 1 and 2 weeks after operation | 3 days and 1 and 2 weeks after operation | |
Secondary | The bleeding time | The bleeding time | From date of randomization until the date of second operation , assessed up to 13 months | |
Secondary | The operation rate of balloon occlusion again | The operation rate of balloon occlusion again | From date of randomization until the date of second operation , assessed up to 13 months | |
Secondary | Measurement indexes of follow-up treatment measures | Including CTA and its preparation time, rate of arterial embolization surgery and proportion of emergency surgery. | From date of randomization until the date of second operation , assessed up to 13 months | |
Secondary | Anesthesia complications | Complications after anesthesia including hypotension and shock, postoperative new tracheal intubation, coma and cerebrovascular accident. | During surgery | |
Secondary | hyoxemia | For more than 2 hours, oxygen saturation drops below 90%. | From date of randomization until the date of second operation , assessed up to 13 months | |
Secondary | Other complications | venous thrombosis of lower limbs | From date of randomization until the date of second operation , assessed up to 13 months | |
Secondary | Balloon closure operation time | Compared with the traditional dilated balloon group, the operation time of balloon closure was calculated | up to 13 months | |
Secondary | success rate of placement | success rate of placement | From date of randomization until death , assessed up to 13 months | |
Secondary | time and incidence of balloon leakage | time and incidence of balloon leakage (under the premise of two inflations per day) | From date of randomization until the date of second operation , assessed up to 13 months | |
Secondary | incidence of balloon displacement | incidence of balloon displacement (including the discount and distortion in the airway) | From date of randomization until the date of second operation , assessed up to 13 months | |
Secondary | Nasal and bronchial mucosa injury | Compared with the traditional dilated balloon group, the damage of nasal and bronchial mucosa after balloon closure was observed | up to 13 months | |
Secondary | Rate of hemoptysis after balloon occlusion | compared with traditional balloon dilation group | up to 13 months | |
Secondary | Rate of re-balloon closure | compared with traditional balloon dilation group | up to 13 months | |
Secondary | Incomplete completion rate of balloon closure operation | compared with traditional balloon dilation group | up to 13 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Completed |
NCT00387374 -
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
|
Phase 2 | |
Completed |
NCT05513248 -
Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019
|
||
Recruiting |
NCT05634200 -
Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan
|
||
Recruiting |
NCT06144398 -
Single Use Flexible Bronchoscopes in Interventional Pulmonary Procedures
|
N/A | |
Completed |
NCT01278199 -
Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance
|
N/A | |
Recruiting |
NCT04961528 -
ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
|
Phase 3 | |
Recruiting |
NCT05786781 -
An Exploratory Study on the Application of Transarterial CT Angiography in the Interventional Treatment of Hemoptysis
|
N/A | |
Completed |
NCT04087135 -
Comparison of Intubation With Direct Laryngoscopy or Videolaryngoscopy in an Hemoptysis Simulated Situation on Human Cadaver Embalmed With Thiel's Method
|
N/A | |
Recruiting |
NCT03270735 -
A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection
|
Phase 4 | |
Completed |
NCT00929565 -
Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
|
N/A | |
Completed |
NCT01171768 -
The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
|
N/A | |
Withdrawn |
NCT01167764 -
Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis
|
Phase 3 | |
Completed |
NCT03126968 -
Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
|
Phase 2/Phase 3 | |
Completed |
NCT02781597 -
Efficacy of Tranexamic Acid in Hemoptysis
|
Phase 3 | |
Recruiting |
NCT05648656 -
TXA Nebulization for the Treatment of Hemoptysis
|
Phase 3 | |
Completed |
NCT04771923 -
Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding
|
N/A | |
Recruiting |
NCT06145191 -
Prophylactic Tranexamic Acid Versus Adrenaline During Flexible Bronchoscopy
|
N/A | |
Completed |
NCT04770675 -
Post Market Study to Collect Data for Software Recognizing the Anatomical Structures During Bronchoscopy.
|
||
Completed |
NCT06067997 -
Prevalence Of Pulmonary Embolism In Patients With HEmoptysis (POPEIHE)
|